Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

NCT00212693•Ono Pharmaceutical Co. Ltd

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

Eligibility

Age

20 - 79 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosis of Parkinson's disease
•2. Stage 2 - Stage 4 of revised Hoehn \& Yahr severity score
•3. Taking L-dopa/DCI without changing dose and regimen
•4. Having motor complication

Exclusion Criteria

•1. Previous participation in ONO-2506PO or ONO-2506 protocol
•2. Previous brain surgery for Parkinson's disease
•3. Presence or history of serious cardiac disease

Key Dates

Start Date

January 1, 2004

Primary Completion Date

September 1, 2005

Last Updated

October 11, 2012

Enrollment

165

Estimated participants

Conditions

Parkinson's Disease

Interventions

ONO-2506PO

DRUG

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 11, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Inclusion Criteria

Exclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations